Please use this identifier to cite or link to this item: doi:10.22028/D291-43561
Title: Real-World Experience of People with Hemophilia A Receiving Turoctocog Alfa Pegol (N8-GP): Results from a Patient Experience Survey
Author(s): Eichler, Hermann
Nagao, Azusa
Waller, John
Stuber, Alexander
Language: English
Title: Patient preference and adherence
Volume: 17
Publisher/Platform: Dove Medical Press
Year of Publication: 2023
Free key words: hemophilia A
turoctocog alfa pegol
patient preference
real-world evidence
patient satisfaction
quality of life
DDC notations: 610 Medicine and health
Publikation type: Journal Article
Abstract: Turoctocog alfa pegol (N8-GP) is an extended half-life recombinant factor VIII molecule used for the treatment of hemophilia A (HA). The purpose of this study was to investigate real-world experiences of patients with HA treated with N8-GP.
DOI of the first publication: 10.2147/PPA.S394216
URL of the first publication: https://pmc.ncbi.nlm.nih.gov/articles/PMC10661914/
Link to this record: urn:nbn:de:bsz:291--ds-435615
hdl:20.500.11880/39030
http://dx.doi.org/10.22028/D291-43561
ISSN: 1177-889X
Date of registration: 26-Nov-2024
Faculty: M - Medizinische Fakultät
Department: M - Chirurgie
Professorship: M - Prof. Dr. Hermann Eichler
Collections:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Files for this record:
File Description SizeFormat 
ppa-17-3001.pdf1,55 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons